Haemonetics (NYSE:HAE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Haemonetics (NYSE:HAE) posted its earnings results on Thursday. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04, FiscalAI reports. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. During the same period in the previous year, the firm posted $1.19 EPS. The business’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics updated its FY 2026 guidance to 4.900-5.000 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Company raised full‑year guidance — reported revenue guidance tightened to a decline of ~1%–3%, organic revenue ex‑CSL raised to ~8%–10%, adjusted EPS now expected at $4.90–$5.00, and free cash flow guidance increased to $200–$220 million.
• Core product momentum — NexSys/TEG and Plasma drove outsized results (TEG adoption and a new heparinase cartridge accelerating conversions; Plasma organic growth ex‑CSL ~20% this quarter and ~22% YTD), with sustained share gains and innovation‑led pricing.
• Interventional Technologies (IVT) remains a drag — IVT revenue fell materially (down 12% Q/Q) due to esophageal cooling weakness, accelerated PFA adoption and OEM headwinds; management expects a turnaround in FY2027 but is investing now, so near‑term performance is challenged.
• Margins and cash generation strengthened — adjusted gross margin ~60%, operating‑margin guidance ~26%–27%, $74M free cash flow in the quarter (YTD $165M), cash balance up to $363M, active buybacks and the $61M Vivisure acquisition funded while keeping leverage manageable.

Haemonetics Stock Down 1.5%

Shares of HAE traded down $0.98 during trading hours on Thursday, reaching $64.98. The company’s stock had a trading volume of 950,047 shares, compared to its average volume of 854,980. The company has a 50 day moving average of $77.59 and a two-hundred day moving average of $65.27. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 19.08, a P/E/G ratio of 1.35 and a beta of 0.28.

Analysts Set New Price Targets

Several analysts have commented on HAE shares. Barrington Research reaffirmed an “outperform” rating and issued a $93.00 target price on shares of Haemonetics in a research note on Monday. Raymond James Financial restated an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Robert W. Baird upped their price objective on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Finally, Mizuho increased their price target on shares of Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and an average price target of $84.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC boosted its holdings in Haemonetics by 372.8% during the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after acquiring an additional 755,592 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Haemonetics in the 3rd quarter worth $15,703,000. Qube Research & Technologies Ltd acquired a new position in shares of Haemonetics in the 3rd quarter valued at about $13,178,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Haemonetics during the 3rd quarter worth $6,145,000. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.